ANNEXIN PHARMACEUTICALS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.297 SEK | +2.41% |
|
+10.00% | +14.23% |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 31.12 | 154.2 | 88.39 | 102.9 | - |
| Enterprise Value (EV) 1 | 27.09 | 154.2 | 66.97 | 84.54 | 102.9 |
| P/E ratio | -1.1 x | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 2.6 x |
| EV / Revenue | - | - | - | - | 2.6 x |
| EV / EBITDA | -1.12 x | -3.8 x | - | -1.62 x | -6.2 x |
| EV / FCF | -1,052,952 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,684 | 154,498 | 339,949 | 346,584 | - |
| Reference price 2 | 1.760 | 0.9980 | 0.2600 | 0.2970 | 0.2970 |
| Announcement Date | 1/28/20 | 2/7/23 | 2/9/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 39.6 |
| EBITDA 1 | -24.1 | - | -40.53 | - | -52.1 | -16.6 |
| EBIT 1 | -28.33 | - | -40.72 | -44.18 | -52.1 | -16.6 |
| Operating Margin | - | - | - | - | - | -41.92% |
| Earnings before Tax (EBT) 1 | -28.36 | - | -40.73 | - | -52.1 | -16.6 |
| Net income 1 | -28.36 | -52.14 | -40.73 | -44.05 | -52.1 | -16.6 |
| Net margin | - | - | - | - | - | -41.92% |
| EPS | -1.600 | - | - | - | - | - |
| Free Cash Flow | -25.72 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/28/20 | 2/3/22 | 2/7/23 | 2/9/24 | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 4.04 | - | - | 21.4 | 18.4 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | -25.7 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 1/28/20 | 2/3/22 | 2/7/23 | 2/9/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.23% | 9.39M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ANNX Stock
- Financials Annexin Pharmaceuticals AB
